Genscript is the world’s leading biotech company providing life sciences services and products, With gene synthesis, peptide, protein, antibody and preclinical drug development service capabilities, we are internationally recognized as a leading biotech company specializing in fundamental life sciences research and early-phase drug discovery services. As of 2018, more than 30,000 peer-reviewed journal articles cited GenScript’s services and products, making GenScript the most frequently cited biotech company in the world.
GenScript Biotech Corp. is the world leader in the biotechnology reagent service industry, as well as an open platform for pre-clinical drugs discovery and pharmaceutical development, driven by innovative technologies. As a public company (HK Stock: 01548), our mission is to make human and nature healthier through biotechnology.
Our mission is to Build world-class protein and antibody engineering platforms and push for revolutionary breakthroughs in support of life science research, industrial enzymes and medical purposes to benefit mankind.
Established in 2002, the company headquarter is located in Nanjing, China, with production and operation center in both Nanjing and New Jersey, United States. There are also branches in EU, an R&D center in Ireland and a logistics center in Netherland, and branch in Japan. With these facilities, we have been serving more than 100 countries and 200,000+ customers around the world for more than 16 years.
Since the first day, we believe the “Human engine” and “Science Engine” are the driving forces of our business. Among 2000+ employees by now, there are more than 700 with master or Ph.D. degree. This percentage is even higher than 90% in our R&D and commercial team. The company has successfully established fully integrated capabilities and services from Gene synthesis, peptide synthesis, protein expression and engineering, custom antibody development and engineering, animal model development, in vitro/in vivo pharmacology as well as a variety of catalog products.
As a leading gene synthesis company, GenScript cofounded IGSC (International Gene Synthesis Consortium), in September of 2009. By screening the sequences of synthetic gene orders and the customers who place them, the IGSC member companies aim to support government efforts to prevent the misuse of gene synthesis technology.
With the outstanding product and service quality, the excellent reputation, and a comprehensive portfolio of patents and trade secrets in synthetic biology, chemical synthesis, protein engineering, antibody engineering, immunotherapy as well as bio-informatics; the company has also build our leading edge in the industry, and close relationship with investors including Kleiner Perkins, Bao Hang Group, China Resources Group and Bexiang Investment Group.
GenScript, a dedicated biology research service provider, has developed a series of partnerships with the following organizations to guarantee the quality of our services and to protect the privacy of our customers’ information. GenScript’s products and services are certified by ISO9001:2015, the current and only valid version of the QMS standard.